36 results
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
18 May 23
January 2024 PDUFA date expected
4:20pm
and recommended for assessment in efficacy trials by the FDA in its current industry guidance document and/or the International Headache Society’s
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
, in each case with the goal of maximizing stockholder value. In furtherance of its review and assessment of the Company, the Company Board
8-K
EX-2.1
STSA
Satsuma Pharmaceuticals Inc
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
, any extension of time with respect to a Tax assessment or deficiency, in each case that is currently in effect.
(f) There are no agreements relating … is considering such action. Neither the Company nor any of its Subsidiaries has been subject to any adverse inspection, finding, penalty assessment or other Legal
8-K
EX-99.1
ctyxj
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.2
8dmn1
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
8-K
EX-99.1
2i58cnc5ys
30 Nov 22
Other Events
4:00pm
8-K
EX-99.1
65gpgkjbhaieyn
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
8-K
EX-99.2
ii03c5a53aj53u1y
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
424B5
2xasi6z838wwz1u9x8p
3 Nov 22
Prospectus supplement for primary offering
4:42pm